Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

117.18
-1.4500-1.22%
Volume:60.88K
Turnover:7.17M
Market Cap:9.74B
PE:-36.48
High:118.72
Open:118.63
Low:116.21
Close:118.63
52wk High:130.05
52wk Low:40.10
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.27
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.46
PE(LYR):-31.76

Loading ...

Truist Securities Adjusts Kymera Therapeutics PT to $136 From $116, Maintains Buy Rating

MT Newswires Live
·
Jun 26

Kymera Therapeutics price target raised to $129 from $106 at Canaccord

TIPRANKS
·
Jun 26

Kymera Therapeutics Chief Business Officer Noah Goodman Disposes of 5,000 Shares for $570,000

Reuters
·
Jun 26

Sector Update: Healthcare

MT Newswires Live
·
Jun 26

Top Midday Gainers

MT Newswires Live
·
Jun 26

Kymera Therapeutics Price Target Maintained with a $134.00/share by BTIG

Dow Jones
·
Jun 26

Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment

TIPRANKS
·
Jun 25

Kymera Therapeutics Shares Jump After Accelerating Kt-621 Trial Timeline

Dow Jones
·
Jun 25

Kymera Therapeutics rises 18.6%

TIPRANKS
·
Jun 25

Analysts Are Bullish on Top Healthcare Stocks: Alpha Teknova (TKNO), Kymera Therapeutics (KYMR)

TIPRANKS
·
Jun 25

Shares of Kymera Therapeutics up 10.2% Premarket After Co Completes Enrollment for Mid-stage Eczema Trial

THOMSON REUTERS
·
Jun 25

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion

MT Newswires Live
·
Jun 25

Kymera Therapeutics - Phase 3 Trials in Atopic Dermatitis Expected to Initiate by Mid-2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics - Kt-621 Breadth Phase 2B Asthma Trial Data Expected in Late 2027

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Completes Enrollment in the Phase 2B Broaden2 Trial of Kt-621 in Atopic Dermatitis with Topline Data by Year-end 2026

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Shareholders Elect Booth, Mainolfi, Maraganore, Ridloff as Class III Directors

Reuters
·
Jun 25

Kymera Therapeutics Names Felix Baker Board Chairman, Replacing Bruce Booth

Reuters
·
Jun 25

Kymera Therapeutics Appoints Felix J. Baker, Ph.d., as Chairman of the Board of Directors

THOMSON REUTERS
·
Jun 25

Kymera Therapeutics Chief Business Officer Noah Goodman reports sale of 2,500 shares worth $247,500

Reuters
·
Jun 23